Sale!

SARS-CoV-2 Nucleoprotein Antibodies (Monoclonal)

$295.00

Catalog Number: B2010387 (100 ug)
Retinol Binding Protein (Native Lyophilized) is a high quality research product used as high affinity rabbit monoclonal antibodies to SARS-CoV-2 Nucleoprotein. These antibodies are highly purified and have been validated in many capture detection systems (such as ELISA, HRP, Biotin and Lateral Flow). Over 20 clones and 15 validated pairs are available. Custom bulk orders of this product are available upon request.
Live Enquiry about this product via Text/SMS: 1-858-900-3210.

In stock

SKU: B2010387 Categories: , ,

Description

Retinol Binding Protein (Native Lyophilized)
Catalog number: B2010387
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 ug
Molecular Weight or Concentration: 150 kDa
Supplied as: Solution
Appearance: Clear Solution
Applications: high affinity rabbit monoclonal antibodies to SARS-CoV-2 Nucleoprotein. These antibodies are highly purified and have been validated in many capture detection systems (such as ELISA, HRP, Biotin and Lateral Flow). Over 20 clones and 15 validated pairs are available.
Storage: -20C
Keywords: SARS-CoV-2 nucleocapsid protein antibody, SARS-CoV-2 NP antibody
Grade: Biotechnology grade. All solid components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Shajahan A, Supekar NT, Gleinich AS, Azadi P. Deducing the N- and
O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2.
Glycobiology. 2020 Dec 9;30(12):981-988.

2: Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F,
Rutkowska M, Hoffmann HH, Michailidis E, Gaebler C, Agudelo M, Cho A, Wang Z,
Gazumyan A, Cipolla M, Luchsinger L, Hillyer CD, Caskey M, Robbiani DF, Rice CM,
Nussenzweig MC, Hatziioannou T, Bieniasz PD. Escape from neutralizing antibodies
by SARS-CoV-2 spike protein variants. Elife. 2020 Oct 28;9:e61312.

3: Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian
S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L,
Zhang J, Xia N, Zhang Z. Antibody Responses to SARS-CoV-2 in Patients With Novel
Coronavirus Disease 2019. Clin Infect Dis. 2020 Nov 19;71(16):2027-2034.

4: Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD,
Takehara KK, Eggenberger J, Hemann EA, Waterman HR, Fahning ML, Chen Y, Hale M,
Rathe J, Stokes C, Wrenn S, Fiala B, Carter L, Hamerman JA, King NP, Gale M Jr,
Campbell DJ, Rawlings DJ, Pepper M. Functional SARS-CoV-2-Specific Immune Memory
Persists after Mild COVID-19. Cell. 2021 Jan 7;184(1):169-183.e17.

5: Barnes CO, Jette CA, Abernathy ME, Dam KA, Esswein SR, Gristick HB, Malyutin
AG, Sharaf NG, Huey-Tubman KE, Lee YE, Robbiani DF, Nussenzweig MC, West AP Jr,
Bjorkman PJ. SARS-CoV-2 neutralizing antibody structures inform therapeutic
strategies. Nature. 2020 Dec;588(7839):682-687.

6: Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z,
Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W,
Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo
W, Yang X. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine,
BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
Lancet Infect Dis. 2021 Jan;21(1):39-51.

7: Yao H, Song Y, Chen Y, Wu N, Xu J, Sun C, Zhang J, Weng T, Zhang Z, Wu Z,
Cheng L, Shi D, Lu X, Lei J, Crispin M, Shi Y, Li L, Li S. Molecular
Architecture of the SARS-CoV-2 Virus. Cell. 2020 Oct 29;183(3):730-738.e13.
8: Finkel Y, Mizrahi O, Nachshon A, Weingarten-Gabbay S, Morgenstern D, Yahalom-
Ronen Y, Tamir H, Achdout H, Stein D, Israeli O, Beth-Din A, Melamed S, Weiss S,
Israely T, Paran N, Schwartz M, Stern-Ginossar N. The coding capacity of SARS-
CoV-2. Nature. 2021 Jan;589(7840):125-130.

Products Related to SARS-CoV-2 Nucleoprotein Antibodies: Antibodies